• By ICR Secretariat
  • Posted Thursday, January 19, 2023

10 clinical trials to watch in the first half of 2023


The biotechnology industry begins 2023 at a crossroads.

In many ways, the sector is coming off of one of its toughest years in recent memory. Initial public offerings ground to a halt. A widely followed biotech stock index plunged nearly 30%. More than 100 companies restructured and cut jobs. And the sector suffered a rare defeat in Washington with the passage of the Inflation Reduction Act, a law meant to lower drug costs.